Garry Menzel, TCR² Therapeutics CEO
TCR²'s gavo-cel survives a PhI test. Now it's head-first into PhII with a half-dozen partial responses
A T cell biotech has some positive results, and now that the data are out, the biotech is moving forward on its next steps. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
